Welcome to the e-CCO Library!

P311: Depression and anxiety are associated with poor clinical outcomes in Inflammatory Bowel Disease : A Nationwide Population-Based Study in South Korea
Year: 2022
Source: ECCO'22
Authors: Kim, S.(1);Seungwoo, L.(2);Kyungdo, H.(2);Hyun Jung , L.(1);Jong Pil , I.(1);Joo Sung, K.(1);
Created: Friday, 11 February 2022, 3:52 PM
P311: Intensive dried blood spot sampling shows a higher drug exposure throughout the first 24 weeks of therapy in ustekinumab-treated Crohn’s disease patients achieving endoscopic remission
Year: 2021
Source: ECCO'21 Virtual
Authors: Van den Berghe, N.(1);Verstockt, B.(2,3);Ballet, V.(2);Gils, A.(1);Sabino, J.(2,3);Ferrante, M.(2,3);Vermeire, S.(2,3);Declerck, P.(1);Thomas, D.(1);
Created: Wednesday, 2 June 2021, 4:12 PM
P311: Microscopic inflammation and myenteric plexitis at the margin of resection do not predict endoscopic recurrence in patients with Crohn's disease after ileocolic resection
Year: 2017
Source: ECCO '17 Barcelona
Authors:

Boland K.*1, Stempak J.1, Weizman A.1, Nguyen G.1, Kennedy E.1, MacRae H.1, Cohen Z.1, Croitoru K.1, Conner J.2, Silverberg M.1

Created: Wednesday, 20 February 2019, 10:36 AM
P311: No difference in immunogenicity of the original and biosimilar infliximab in patients with inflammatory bowel disease: short-term results
Year: 2016
Source: ECCO '16 Amsterdam
Authors:

K. Malickova1, D. Duricova*2, M. Kolar2, M. Bortlik2, V. Hruba2, N. Machkova2, K. Mitrova2, M. Lukas Jr.2, M. Lukas2

Created: Friday, 22 February 2019, 9:49 AM
P311: Pharmacokinetics and exposure–response relationships of intravenously administered ustekinumab during induction treatment in patients with ulcerative colitis: Results from the UNIFI induction study
Year: 2019
Source:

ECCO '19 Copenhagen

Authors:

O. J. Adedokun*1, Z. Xu1, C. Marano1, C. D. O'Brien1, P. Szapary1, H. Zhang1, J. Johanns1, R. W. Leong2,3, T. Hisamatsu4, G. Van Assche5, S. Danese6, M. T. Abreu7, B. E. Sands8, W. J. Sandborn9

Created: Friday, 22 February 2019, 9:41 AM
P311: Reliability of computed tomography enterography for evaluation of stricturing Crohn's disease: Development of a Crohn's disease stricture index
Year: 2023
Source: ECCO’23 Copenhagen
Authors: Rieder, F.(1)*;Ma, C.(2);Hanzel, J.(3);Fletcher, J.G.(4);Baker, M.(5);Wang, Z.(6);Guizetti, L.(6);Patel, M.(1);Niu, J.(1);Shackelton, L.(6);Ottichilo, R.(7);Santillan, C.(8);Capozzi, N.(9);Taylor, S.A.(10);Zhou, G.(6);Bruining, D.(11);Feagan, B.(12);Jairath, V.(12);Rimola, J.(9);
Created: Friday, 14 July 2023, 11:05 AM
P312 Introduction of bowel ultrasonography for follow-up of paediatric inflammatory bowel disease: A single-centre experience
Year: 2020
Source:

ECCO'20 Vienna

Authors:

R. Lev Zion, G. Focht, N. Asayag, D. Turner

Created: Thursday, 30 January 2020, 10:12 AM
P312: Combination corticosteroids with 5-aminosalicylic acid versus corticosteroids alone in the treatment of hospitalized patients with acute severe ulcerative colitis: A multi-center randomized controlled trial
Year: 2022
Source: ECCO'22
Authors: Ben-Horin, S.(1,2);Har-Noy, O.(1);Katsanos, K.H.(3);Xavier, R.(4);Chen, M.H.(2);Gao, X.(5);Schwartz, D.(6);Cheon, J.H.(7);Cesarini, M.(8);Bojic, D.(9);Protic, M.(9);Theodoropoulou, A.(10);Abu-Kaf, H.(6);Engel, T.(1);Tang, J.(5);Veyrard, P.(4);Lin, X.(2);Mao, R.(2);Christodoulou, D.(3);Karmiris, K.(10);Knezevic-Ivanovski, T.(9);
Created: Friday, 11 February 2022, 3:52 PM
P312: Efficacy in biologic failure and non-biologic-failure populations in a Phase 3 study of ustekinumab in moderate–severe ulcerative colitis: UNIFI
Year: 2019
Source:

ECCO '19 Copenhagen

Authors:

B. E. Sands*1, L. Peyrin-Biroulet2, C. Marano3, C. D. O'Brien3, H. Zhang3, J. Johanns4, P. Szapary3, D. Rowbotham5,6, R. W. Leong7,8, R. P. Arasaradnam9, S. Danese10, G. Van Assche11, S. Targan12, W. J. Sandborn13

Created: Friday, 22 February 2019, 9:41 AM
P312: Erythrocyte methotrexate polyglutamate concentrations in patients with Crohn's Disease: towards a new therapeutic drug monitoring tool
Year: 2021
Source: ECCO'21 Virtual
Authors: Van De Meeberg, M.(1);Lin, M.(2);Seinen, M.(3);Fidder, H.(4);Oldenburg, B.(4);Bouma, G.(1);de Jonge, R.(2);Bulatović Ćalasan, M.(5);
Created: Wednesday, 2 June 2021, 4:12 PM
P312: Has IBD specialists’ awareness of biosimilar monoclonal antibodies changed? Results from a survey amongst ECCO members
Year: 2016
Source: ECCO '16 Amsterdam
Authors:

S. Danese*1, 2, G. Fiorino1, P. Michetti3

Created: Friday, 22 February 2019, 9:49 AM
P312: Retrospective study using ultrasonography in predicting clinical relapse of Crohn's disease
Year: 2023
Source: ECCO’23 Copenhagen
Authors: Fukushima, S.(1)*;Katsurada, T.(1);Keiya, A.(1);Sakurai, K.(1);Yamanashi, K.(2);Omotehara, S.(3);Onishi, R.(1);Nishida, M.(3);Sakamoto, N.(1);
Created: Friday, 14 July 2023, 11:05 AM
P312: The value of faecal biomarkers for screening small bowel inflammation in patients with Crohn’s disease
Year: 2018
Source: ECCO '18 Vienna
Authors:

T. Yamamoto*, T. Shimoyama, S. Umegae

Created: Thursday, 21 February 2019, 9:14 AM
P312: Trabecular bone score in patients with inflammatory bowel diseases
Year: 2017
Source: ECCO '17 Barcelona
Authors:

Krajcovicova A., Hlavaty T., Killinger Z., Kuzma M., Sturdik I., Leskova Z., Payer J.

Created: Wednesday, 20 February 2019, 10:36 AM
P313 Time to second pouchitis episode in a Dutch academic cohort
Year: 2020
Source:

ECCO'20 Vienna

Authors:

D.C. de Jong1, K. Wasmann2, C. Buskens2, W. Bemelman2, M. Löwenberg1, K. Gecse1, C. Ponsioen1, G. D’Haens1, R. Hompes2, M. Duijvestein1

Created: Thursday, 30 January 2020, 10:12 AM
P313: Comparison of accelerated infliximab induction versus standard induction treatment in acute severe ulcerative colitis
Year: 2016
Source: ECCO '16 Amsterdam
Authors:

M. Choy*1, 2, 3, D. Seah1, 3, A. Gorelik4, F. Macrae5, M. Sparrow6, W. R. Connell2, G. Moore7, D. Van Langenberg8, P. De Cruz1, 3

Created: Friday, 22 February 2019, 9:49 AM
P313: Glycan antibodies and pANCA in newly diagnosed inflammatory bowel disease patients at presentation and during follow-up
Year: 2017
Source: ECCO '17 Barcelona
Authors:

Smids C.*1, Horjus Talabur Horje C.1, Groenen M.1, van Koolwijk E.2, Wahab P.1, van Lochem E.2

Created: Wednesday, 20 February 2019, 10:36 AM
P313: Impact of upadacitinib on the general clinical condition of patients with Crohn’s disease (CD): data from the randomised CELEST study
Year: 2019
Source:

ECCO '19 Copenhagen

Authors:

E. V. Loftus Jr*1, D. T. Rubin2, J. Panes3, D. Pugatch4, W. Zhou4, S. Goteti4, A. Lacerda4, S. Travis5

Created: Friday, 22 February 2019, 9:41 AM
P313: Long-term durability and safety of anti-TNF agents compared with change to a different mechanism of action as a second-line biological treatment after first anti-TNF failure in Crohn´s disease: results from the Andalusian CambiaCrohn study
Year: 2021
Source: ECCO'21 Virtual
Authors: Vázquez Morón, J.M.(1);Martínez Rodríguez, M.D.M.(2);Olmedo Martin, R.(3);Hernández Martínez, Á.(4);Núñez Ortiz, A.(5);Rueda Sánchez, J.(6);Argüelles Arias, F.(7);Caballero Mateos, A.(8);Iglesias Flores, E.(9);Viejo Almanzor, A.(10);Pallarés Manrique, H.(11);
Created: Wednesday, 2 June 2021, 4:12 PM
P313: Steroid and opioid use among Crohn’s patients before and after initiation of ustekinumab
Year: 2018
Source: ECCO '18 Vienna
Authors:

C. Obando1*, K. Woodruff1, E. Muser1, C. Gasink1, T. Hoops1, T. Slaton2, C.M. Kozma2

Created: Thursday, 21 February 2019, 9:14 AM